It has been postulated that hormone therapy may benefit patients with hypergonadotropic hypogonadism by using GnRH to suppress gonadotrophin levels and thereby overcoming Sertoli cell receptor desensitization caused by chronically raised FSH levels (Foresta et al., 2004, 2009). Here, BRD2 is linked to Hypergonadotropic hypogonadism.